TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC.
Brief Summary: The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.


Options:
A: Arm Label: Arm A BIBW 2992; Type: EXPERIMENTAL; Interventions: Drug: BIBW 2992 | Arm Label: Arm B Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine+Cisplatin | Intervention Type: DRUG; Name: Gemcitabine+Cisplatin; Assigned to Arm(s): Arm B Chemotherapy | Intervention Type: DRUG; Name: BIBW 2992; Assigned to Arm(s): Arm A BIBW 2992
B: Arm Label: Cetuximab plus chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: cetuximab + cisplatin + vinorelbine | Arm Label: Chemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin + vinorelbine | Intervention Type: DRUG; Name: cetuximab + cisplatin + vinorelbine; Assigned to Arm(s): Cetuximab plus chemotherapy | Intervention Type: DRUG; Name: cisplatin + vinorelbine; Assigned to Arm(s): Chemotherapy alone
C: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Platinum chemotherapy (cisplatin or carboplatin), Drug: erlotinib [Tarceva], Drug: gemcitabine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Platinum chemotherapy (cisplatin or carboplatin), Drug: gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Platinum chemotherapy (cisplatin or carboplatin); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: erlotinib [Tarceva]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective,Randomised, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Bilateral Globus Pallidus Internus - in Patients With Medically Refractory Primary Cervical Dystonia
Brief Summary: The purpose of this study is to investigate the efficacy and safety of bilateral pallidal stimulation in patients with medically refractory primary cervical dystonia.


Options:
A: Intervention Type: DEVICE; Name: Deep brain stimulation of the internal globus pallidus; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Deep brain stimulation; Assigned to Arm(s): N/A
C: Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Deep brain stimulation (DBS) | Intervention Type: DEVICE; Name: Deep brain stimulation (DBS); Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Bilateral Deep Brain Stimulation | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: best medical therapy | Intervention Type: DEVICE; Name: Bilateral Deep Brain Stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: best medical therapy; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "The CHRONOS Study: Can the Sleep-deprivation Induced Antidepressive Effect in Patients With Major Depression be Sustained by Correction of Diurnal Rhythms, Long Term Light Treatment and Duloxetine Treatment?"
Brief Summary: The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Aerobic Exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Pill. | Intervention Type: BEHAVIORAL; Name: Supervised Aerobic Exercise; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Pill.; Assigned to Arm(s): 3
C: Intervention Type: BEHAVIORAL; Name: Supervised Exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Home-Based Exercise; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline (Zoloft); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo Pill; Assigned to Arm(s): N/A
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Sleep deprivation, Procedure: Light therapy, Procedure: Diurnal rhythms, Drug: duloxetine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Drug: duloxetine | Intervention Type: PROCEDURE; Name: Sleep deprivation; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Light therapy; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Diurnal rhythms; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): B | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients
Brief Summary: Major burns trigger the release of circulating mediators, as cytokines and endotoxin that induces a systemic inflammatory response syndrome. The cardiovascular effects are similar to those seen in septic shock. After the initial hypovolemic phase, patients with extensive burns often present a shock with increased cardiac output and reduced systemic vascular resistances. As described in septic shock, we test the hypothesis that low-dose hydrocortisone could decrease the duration of the shock period.


Options:
A: Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: Sterile air filled vial; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile air filled vial | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Sterile air filled vial; Assigned to Arm(s): Sterile air filled vial
B: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Arm Label: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): hydrocortisone | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): Placebo
D: Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-dose Hydrocortisone in the Treatment of the Shock of Burned Patients
Brief Summary: Major burns trigger the release of circulating mediators, as cytokines and endotoxin that induces a systemic inflammatory response syndrome. The cardiovascular effects are similar to those seen in septic shock. After the initial hypovolemic phase, patients with extensive burns often present a shock with increased cardiac output and reduced systemic vascular resistances. As described in septic shock, we test the hypothesis that low-dose hydrocortisone could decrease the duration of the shock period.


Options:
A: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A
B: Arm Label: Prednisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Prednisone
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebos | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrocortisone and fludrocortisone and placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and placebos | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone | Intervention Type: DRUG; Name: placebos; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hydrocortisone and fludrocortisone and placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: recombinant human activated protein C and placebos; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: recombinant human activated protein C and hydrocortisone and fludrocortisone; Assigned to Arm(s): 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone sodium succinate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: hydrocortisone sodium succinate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Comparison of LY2140023, Olanzapine, and Placebo in the Treatment of Patients With Schizophrenia
Brief Summary: Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia.

The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.


Options:
A: Intervention Type: DRUG; Name: risperidone, quetiapine; Assigned to Arm(s): N/A
B: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Comparison of LY2140023, Olanzapine, and Placebo in the Treatment of Patients With Schizophrenia
Brief Summary: Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic activity) in the treatment of schizophrenia.

The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28 days is superior to placebo in the treatment of patients with schizophrenia as measured by the Positive and Negative Symptom Scales (PANSS) total score.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5
B: Arm Label: Iloperidone; Type: EXPERIMENTAL; Interventions: Drug: Iloperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Iloperidone; Assigned to Arm(s): Iloperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MK-0777 8 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: MK-0777 3 mg; Type: EXPERIMENTAL; Interventions: Drug: MK-0777 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 8 mg | Intervention Type: DRUG; Name: MK-0777; Assigned to Arm(s): MK-0777 3 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): LY2140023 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Pro-brain-natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?
Brief Summary: The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.


Options:
A: Arm Label: Usual Care; Type: EXPERIMENTAL; Interventions: Other: Usual Care | Arm Label: Biomarker-Guided Care; Type: EXPERIMENTAL; Interventions: Device: Biomarker-guided care NT-proBNP | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care | Intervention Type: DEVICE; Name: Biomarker-guided care NT-proBNP; Assigned to Arm(s): Biomarker-Guided Care
B: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
D: Arm Label: Darapladib; Type: EXPERIMENTAL; Interventions: Drug: Darapladib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darapladib; Assigned to Arm(s): Darapladib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Pro-brain-natriuretic Peptide Guided Therapy of Chronic Heart Failure Improve Heart Failure Morbidity and Mortality?
Brief Summary: The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: OTHER; Interventions: Other: Intervention Care | Intervention Type: OTHER; Name: Intervention Care; Assigned to Arm(s): Intervention
B: Arm Label: SOC; Type: PLACEBO_COMPARATOR; Interventions: Other: Drug therapy for HF | Arm Label: NT-proBNP arm; Type: ACTIVE_COMPARATOR; Interventions: Other: NT-proBNP guided HF therapy | Intervention Type: OTHER; Name: Drug therapy for HF; Assigned to Arm(s): SOC | Intervention Type: OTHER; Name: NT-proBNP guided HF therapy; Assigned to Arm(s): NT-proBNP arm
C: Arm Label: Heart Failure; Type: N/A; Interventions: N/A
D: Arm Label: NT-proBNP guided treatment group; Type: ACTIVE_COMPARATOR; Interventions: Device: NT-proBNP measurements | Arm Label: Clinically guided arm; Type: PLACEBO_COMPARATOR; Interventions: Device: NT-proBNP measurements | Intervention Type: DEVICE; Name: NT-proBNP measurements; Assigned to Arm(s): Clinically guided arm, NT-proBNP guided treatment group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Social Support and Education in Asthma Follow-up (SSEA)
Brief Summary: We will evaluate the effect of an eighteen-month asthma coaching intervention for parents/caregivers of children with asthma to reduce asthma morbidity. The primary objective is to determine if asthma coaching will significantly reduce asthma morbidity as measured by a reduction in the number of ED visits and hospitalizations for the children during the 18 months of active coaching and during the 18 months after the coaching stops.

We will provide half of the subjects (parents/caregivers) with access to assistance from an asthma coach for 18 months (including 2 contacts with an asthma nurse during the first 6 months). The other half of the subjects will not have an asthma coach, but their children will have their usual routine care with their primary care providers. The nurse and coach will help the subjects learn more about caring for their children's asthma and improving interactions with the primary care providers for their children.


Options:
A: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
B: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
C: Arm Label: Wait List; Type: OTHER; Interventions: Behavioral: Wait list comparison group | Arm Label: 2 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 2 Family-based problem solving phone sessions | Arm Label: 4 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 4 Family-based problem solving phone intervention sessions | Intervention Type: BEHAVIORAL; Name: 2 Family-based problem solving phone sessions; Assigned to Arm(s): 2 phone sessions | Intervention Type: BEHAVIORAL; Name: 4 Family-based problem solving phone intervention sessions; Assigned to Arm(s): 4 phone sessions | Intervention Type: BEHAVIORAL; Name: Wait list comparison group; Assigned to Arm(s): Wait List
D: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Social Support and Education in Asthma Follow-up (SSEA)
Brief Summary: We will evaluate the effect of an eighteen-month asthma coaching intervention for parents/caregivers of children with asthma to reduce asthma morbidity. The primary objective is to determine if asthma coaching will significantly reduce asthma morbidity as measured by a reduction in the number of ED visits and hospitalizations for the children during the 18 months of active coaching and during the 18 months after the coaching stops.

We will provide half of the subjects (parents/caregivers) with access to assistance from an asthma coach for 18 months (including 2 contacts with an asthma nurse during the first 6 months). The other half of the subjects will not have an asthma coach, but their children will have their usual routine care with their primary care providers. The nurse and coach will help the subjects learn more about caring for their children's asthma and improving interactions with the primary care providers for their children.


Options:
A: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
B: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Asthma Program | Intervention Type: BEHAVIORAL; Name: Telephone Asthma Program; Assigned to Arm(s): Intervention
D: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes

Answer: D